Coupling metal-organic framework nanosphere and nanobody for boosted photoelectrochemical immunoassay of Human Epididymis Protein 4
Coupling metal-organic framework nanosphere and nanobody for boosted photoelectrochemical immunoassay of Human Epididymis Protein 4
复制标题
耦合金属有机框架纳米球和纳米抗体增强人附睾蛋白 4 的光电化学免疫分析
DOI：
10.1016/j.aca.2020.02.011
复制
发表时间：
2020-04-22
影响因子：
6.2
通讯作者：
Shen, Yanfei
中科院分区：
文献类型：
--
作者：
Chen, Kaiyang;Xue, Jiyang;Shen, Yanfei
将卟啉金属有机骨架（MOF）纳米球（nPCN-224）与纳米抗体（Nb）偶联，制备了一种用于检测小分子卵巢癌血清标志物人附睾蛋白4（HE 4）的“信号开启”光电化学（PEC）免疫传感器。采用溶剂热法制备了平均粒径为160-200 nm的nPCN-224，用于Nb的标记。系统研究了nPCN-224光电流产生的机理，结果表明，水溶液中溶解的O-2通过产生O-2（-）参与了光电转换过程中的电荷分离和传输，抗坏血酸作为O-2（-）清除剂可使nPCN-224光电流增强6倍.此外，nPCN-224的固有结构孔隙率证明了反应物可及性的优势。由于nPCN-224的上级性质和Nbs的高特异性和亲和性，免疫传感器表现出宽的检测范围从1.00 pg mL（-1）到10.0 ng mL（-1），检测限为0.560 pg mL（-1），低于以前报道的大多数方法。该免疫传感器可清晰地区分不同阶段的卵巢癌患者和健康个体，所得结果与医院传统的电化学发光免疫分析法结果吻合良好。这项工作将为PEC免疫传感器在临床诊断和潜在临床疗效评价中开辟新的途径。(C)2020 Elsevier B. V.保留所有权利。
A "signal-on" photoelectrochemical (PEC) immunosensor for highly sensitive detection of Human Epididymis Protein 4 (HE4), a new serum biomarker of ovarian cancer with small molecular weight, was fabricated by coupling the porphyrin-based metal-organic framework (MOF) nanosphere (nPCN-224) and Nanobody (Nb). To label the Nb, the nPCN-224 with an average size of 160-200 nm was prepared by solvothermal method. The mechanism for the photocurrent generation of nPCN-224 was systematically investigated, showing that the dissolved O-2 in aqueous solution participated in the charge separation and transport during the photoelectric conversion by generating O-2(-), which resulted in a 6-fold enhanced photocurrent by using ascorbic acid as the O-2(-) scavenger. Moreover, the inherent structural porosity of nPCN-224 demonstrated advantage for reactant accessibility. Due to the superior properties of nPCN-224, and the high specificity and affinity of Nbs, the immunosensor exhibited a broad detection range from 1.00 pg mL(-1) to 10.0 ng mL(-1) and a detection limit of 0.560 pg mL(-1), lower than most methods reported before. The immunosensor could clearly distinguish ovarian cancer patients in different stages from healthy individuals, and the as-obtained results matched well with those by traditional electrochemiluminescence immunoassay method from the hospital. This work would open a new avenue for PEC immunosensors in clinical diagnostics and evaluation of potential clinical efficacy. (C) 2020 Elsevier B.V. All rights reserved.